

Jason Gotlib

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1558689/jason-gotlib-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

169
papers

7,720
citations

37
h-index

87
g-index

231
ext. papers

9,335
ext. citations

6.4
avg, IF

6.14
L-index

#	Paper	IF	Citations
169	A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. <i>New England Journal of Medicine</i> , 2003 , 348, 1201-14	59.2	1426
168	A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. <i>New England Journal of Medicine</i> , 2012 , 366, 799-807	59.2	1377
167	Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. <i>Journal of Allergy and Clinical Immunology</i> , 2012 , 130, 607-612.e9	11.5	430
166	Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. <i>New England Journal of Medicine</i> , 2013 , 368, 1781-90	59.2	388
165	Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. <i>New England Journal of Medicine</i> , 2016 , 374, 2530-41	59.2	269
164	The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. <i>Blood</i> , 2004 , 103, 2879-91	2.3	232
163	Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. <i>Blood</i> , 2005 , 106, 2865-70	2.2	211
162	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 137, 35-45	11.5	209
161	PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRβ-induced myeloproliferative disease. <i>Cancer Cell</i> , 2003 , 3, 459-69	24.3	208
160	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. <i>Cancer Research</i> , 2017 , 77, 1261-1270	10.1	162
159	Myeloid neoplasms with eosinophilia. <i>Blood</i> , 2017 , 129, 704-714	2.2	143
158	The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. <i>Blood</i> , 2013 , 122, 1707-11	2.2	128
157	Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. <i>Mayo Clinic Proceedings</i> , 2010 , 85, 158-64	6.4	118
156	World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2017 , 92, 1243-1259	7.1	111
155	Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. <i>Expert Review of Hematology</i> , 2012 , 5, 157-76	2.8	108
154	Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019 , 7, 1125-1133.e1	5.4	106
153	World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2014 , 89, 325-37	7.1	95

152	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. <i>Blood</i> , 2013 , 121, 2393-401	2.2	89
151	World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2019 , 94, 1149-1167	7.1	86
150	World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2015 , 90, 1077-89	7.1	81
149	Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. <i>Acta Haematologica</i> , 2005 , 114, 7-25	2.7	73
148	JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. <i>Expert Review of Hematology</i> , 2010 , 3, 323-37	2.8	65
147	Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. <i>Nature Medicine</i> , 2015 , 21, 71-5	50.5	60
146	KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. <i>Blood</i> , 2011 , 118, 1885-98	2.2	60
145	World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2011 , 86, 677-88	7.1	53
144	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1348-1356	4.7	51
143	Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. <i>Best Practice and Research in Clinical Haematology</i> , 2006 , 19, 535-69	4.2	48
142	Intricate and Cell Type-Specific Populations of Endogenous Circular DNA (eccDNA) in and. <i>G3: Genes, Genomes, Genetics</i> , 2017 , 7, 3295-3303	3.2	47
141	Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. <i>Haematologica</i> , 2016 , 101, 1133-1143	6.6	46
140	New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis. <i>Blood</i> , 2020 , 135, 1365-1376	2.2	45
139	NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 1505-1512	7.3	44
138	International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. <i>Lancet Haematology</i> , 2019 , 6, e638-e649	14.6	42
137	Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge. <i>American Journal of Hematology</i> , 2010 , 85, 600-6	7.1	42
136	MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2846-2856	2.2	41
135	How I treat atypical chronic myeloid leukemia. <i>Blood</i> , 2017 , 129, 838-845	2.2	40

134	Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. <i>Theranostics</i> , 2020 , 10, 10743-10768	12.1	40
133	KIT mutations in mastocytosis and their potential as therapeutic targets. <i>Immunology and Allergy Clinics of North America</i> , 2006 , 26, 575-92	3.3	38
132	World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2012 , 87, 903-14	7.1	37
131	A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2009 , 84, 15-20	7.1	33
130	The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I. <i>Clinical Cancer Research</i> , 2016 , 22, 757-64	12.9	32
129	Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis. <i>Blood</i> , 2013 , 122, 108-108	2.2	30
128	PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks. <i>Blood</i> , 2015 , 126, 56-56	2.2	27
127	Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts . <i>Blood</i> , 2016 , 128, LBA-5-LBA-5	2.2	27
126	KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial. <i>Blood</i> , 2010 , 116, 316-316	2.2	25
125	The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019 , 7, 81-87	5.4	24
124	Eosinophilic myeloid disorders: new classification and novel therapeutic strategies. <i>Current Opinion in Hematology</i> , 2010 , 17, 117-24	3.3	22
123	ICON: Eosinophil Disorders. <i>World Allergy Organization Journal</i> , 2012 , 5, 174-81	5.2	20
122	Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 2016 , 57, 609-15	1.9	19
121	Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 424-34	7.3	18
120	Tipifarnib (ZARNESTRATM in Previously Untreated Poor-Risk AML of the Elderly: Updated Results of a Multicenter Phase 2 Trial.. <i>Blood</i> , 2004 , 104, 874-874	2.2	18
119	Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I. <i>Blood</i> , 2013 , 122, 396-396	2.2	18
118	Hereditary erythrocytosis, thrombocytosis and neutrophilia. <i>Best Practice and Research in Clinical Haematology</i> , 2014 , 27, 95-106	4.2	17
117	Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. <i>EBioMedicine</i> , 2017 , 26, 17-24	8.8	17

116	Current and future status of JAK inhibitors. <i>Lancet, The</i> , 2021 , 398, 803-816	4.0	17
115	Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1274-81	4.7	16
114	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.. <i>HemaSphere</i> , 2021 , 5, e646	0.3	16
113	Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. <i>Psychophysiology</i> , 2005 , 4, 77-84		16
112	Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2020 , 146, 356-366.e4	11.5	15
111	Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020 , 75, 1927-1938	9.3	15
110	Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis. <i>Hematology/Oncology Clinics of North America</i> , 2017 , 31, 643-661	3.1	15
109	KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial. <i>Blood</i> , 2012 , 120, 799-799	2.2	15
108	The new tool "" in advanced systemic mastocytosis. <i>Hematology American Society of Hematology Education Program</i> , 2018 , 2018, 127-136	3.1	14
107	Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells. <i>Blood Advances</i> , 2018 , 2, 1580-1584	7.8	14
106	Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit). <i>Cancer Medicine</i> , 2018 , 7, 4447-4455	4.8	13
105	Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2017 , 12, 432-441	4.4	13
104	A Phase I Study of TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, in Patients with Myelofibrosis. <i>Blood</i> , 2008 , 112, 97-97	2.2	12
103	Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial. <i>Blood</i> , 2014 , 124, 636-636	2.2	12
102	Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. <i>Leukemia</i> , 2020 , 34, 1090-1101	10.7	12
101	Myeloid and lymphoid neoplasms with FGFR1 abnormalities: diagnostic and therapeutic challenges. <i>American Journal of Hematology</i> , 2013 , 88, 427-30	7.1	11
100	A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia. <i>Blood</i> , 2011 , 118, 6988-90	2.2	11
99	Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. <i>Nature Medicine</i> , 2021 ,	50.5	11

98	Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis. <i>Current Hematologic Malignancy Reports</i> , 2018 , 13, 407-416	4.4	11
97	Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2700-2707	1.9	10
96	A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia. <i>Cancer Genetics</i> , 2017 , 216-217, 10-15	2.3	10
95	Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. <i>Nature Medicine</i> , 2021 ,	50.5	10
94	Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1248-1269	7.3	10
93	World Health Organization-defined eosinophilic disorders: 2021 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2021 ,	7.1	10
92	Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2014 , 38, 1441-5	2.7	9
91	Comprehensive whole-genome sequencing of an early-stage primary myelofibrosis patient defines low mutational burden and non-recurrent candidate genes. <i>Haematologica</i> , 2013 , 98, 1689-96	6.6	9
90	Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. <i>Theranostics</i> , 2021 , 11, 292-303	12.1	9
89	Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2017 , 92, E66-E68	7.1	8
88	Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis. <i>Current Hematologic Malignancy Reports</i> , 2015 , 10, 351-61	4.4	8
87	Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I. <i>Blood</i> , 2011 , 118, 278-278	2.2	8
86	A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. <i>Blood Advances</i> , 2019 , 3, 2264-2271	7.8	8
85	Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	7
84	The KIT Tyrosine Kinase Inhibitor Midostaurine (PKC412) Exhibits a High Response Rate in Aggressive Systemic Mastocytosis (ASM): Interim Results of a Phase II Trial.. <i>Blood</i> , 2007 , 110, 3536-3536 ^{2.2}	2.2	6
83	Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial. <i>Blood</i> , 2013 , 122, 106-106	2.2	6
82	Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. <i>Hematological Oncology</i> , 2019 , 37, 240-252	1.3	5
81	Pure Pathologic Response Is Associated with Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib in the Phase I EXPLORER Study. <i>Blood</i> , 2020 , 136, 37-38	2.2	5

80	Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	5
79	New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1075-1083	1.9	5
78	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). <i>Blood Advances</i> , 2021 , 5, 2481-2489	7.8	5
77	Variability of PD-L1 expression in mastocytosis. <i>Blood Advances</i> , 2018 , 2, 189-199	7.8	5
76	Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. <i>Leukemia</i> , 2021 ,	10.7	5
75	Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 697-703.e1	2	4
74	When yellow jackets attack: recurrent and severe anaphylactic reactions to insect bites and stings. <i>American Journal of Hematology</i> , 2009 , 84, 843-6	7.1	4
73	Missplicing of Glycogen Synthase Kinase 3 α Potential Mechanism of Blast Crisis Chronic Myeloid Leukemia Stem Cell Generation.. <i>Blood</i> , 2007 , 110, 775-775	2.2	4
72	Cycling Toward Leukemia Stem Cell Elimination With a Selective Sonic Hedgehog Antagonist,. <i>Blood</i> , 2011 , 118, 3776-3776	2.2	4
71	Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis. <i>Blood</i> , 2013 , 122, 2823-2823 ^{2,2}	2.2	4
70	Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 1719-1727	4.3	4
69	Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 487-498	5.4	4
68	SOHO State-of-the-Art Update and Next Questions: MPN. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 1-12	2	4
67	Dynamic and Time-to-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-Naïve Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib. <i>Blood</i> , 2019 , 134, 1663-1663	2.2	3
66	GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable By Combined PI3K/mTOR Inhibition. <i>Blood</i> , 2014 , 124, 3567-3567	2.2	3
65	Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. <i>American Journal of Hematology</i> , 2020 , 95, E1-E3	7.1	3
64	Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021 , 9, 1705-1712.e4	5.4	3
63	Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF). <i>Leukemia Research</i> , 2021 , 108, 106606	2.7	3

62	A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2016 , 173, 253-9	4.5	2
61	Antiangiogenic therapy in myelodysplastic syndromes: is there a role?. <i>Current Hematologic Malignancy Reports</i> , 2008 , 3, 10-8	4.4	2
60	Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy. <i>Blood</i> , 2019 , 134, 2950-2950	2.2	2
59	The Platelet-Derived Growth Factor Receptor beta Fuses to Two Distinct Loci at 3p21 in Imatinib Responsive Chronic Eosinophilic Leukemia.. <i>Blood</i> , 2005 , 106, 3253-3253	2.2	2
58	Phase II Trial of the Tyrosine Kinase Inhibitor PKC412 in Advanced Systemic Mastocytosis: Preliminary Results.. <i>Blood</i> , 2006 , 108, 3609-3609	2.2	2
57	Inhibition of JAK2 V617F-Induced Erythroid Skewing of Hematopoietic Stem Cell Differentiation with a Selective JAK2 Antagonist.. <i>Blood</i> , 2006 , 108, 3616-3616	2.2	2
56	Estimation of JAK2 V617F Prevalence by Detection of the Mutation in Saliva Samples From Online MPN and General Population Cohorts. <i>Blood</i> , 2012 , 120, 1737-1737	2.2	2
55	A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM). <i>Blood</i> , 2014 , 124, 1826-1826	2.2	2
54	A Recombinant Antibody to Siglec-8 Shows Selective ADCC Activity Against Mast Cells from Systemic Mastocytosis Patients. <i>Blood</i> , 2015 , 126, 4092-4092	2.2	2
53	Mutation of the Calreticulin (CALR) Gene in Myeloproliferative Neoplasms 2015 , 12,		2
52	Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms. <i>Cell Reports Medicine</i> , 2021 , 2, 100425	18	2
51	Identification of Novel LNK Mutations In Patients with Chronic Myeloproliferative Neoplasms and Related Disorders. <i>Blood</i> , 2010 , 116, 315-315	2.2	2
50	Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. <i>International Journal of Laboratory Hematology</i> , 2021 , 43, e19-e25	2.5	2
49	Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance. <i>Blood Advances</i> , 2021 , 5, 3492-3496	7.8	2
48	A novel activating JAK1 mutation in chronic eosinophilic leukemia. <i>Blood Advances</i> , 2021 , 5, 3581-3586	7.8	2
47	Novel biospecific agents for the treatment of myelodysplastic syndromes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2003 , 1, 473-80	7.3	1
46	Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. <i>Blood</i> , 2020 , 136, 39-40	2.2	1
45	Identification of a Novel Splice Donor Mutation In the Thrombopoietin Gene In a Philippine Family with Hereditary Thrombocythemia. <i>Blood</i> , 2010 , 116, 3086-3086	2.2	1

44	The Impact of Distance to Treatment Center on the Outcome of AML. <i>Blood</i> , 2010 , 116, 4742-4742	2.2	1
43	BCL2 Spline Isoform Switching Promotes Leukemia Stem Cell Survival and Sensitivity to a Novel Pan BCL2 Inhibitor. <i>Blood</i> , 2011 , 118, 2735-2735	2.2	1
42	A Germline Variant in the TERT Gene Is a Novel Predisposition Allele Associated with Myeloproliferative Neoplasms. <i>Blood</i> , 2012 , 120, 707-707	2.2	1
41	PI3K Inhibitor Idelalisib Inhibits AKT Signaling In Myelofibrosis Patients On Chronic JAK Inhibitor Therapy. <i>Blood</i> , 2013 , 122, 4065-4065	2.2	1
40	Hydroxyurea Leukemogenicity in Myeloproliferative Neoplasms: A Not Guilty Verdict 2011 , 8,		1
39	A Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Advanced Systemic Mastocytosis (AdvSM). <i>Blood</i> , 2021 , 138, 3636-3636	2.2	1
38	Effective Control of Advance Systemic Mastocytosis with Avapritinib: Mutational Analysis from the Explorer Clinical Study. <i>Blood</i> , 2021 , 138, 318-318	2.2	1
37	Inhibition of Chronic Myelogenous Leukemia Stem Cells with Novel Wnt Antagonists.. <i>Blood</i> , 2006 , 108, 238-238	2.2	1
36	FDA-Approved Ruxolitinib in Patients with Myelofibrosis: the Stanford Experience. <i>Blood</i> , 2012 , 120, 1747-1747	2.2	1
35	Non-hematologic diagnosis of systemic mastocytosis: Collaboration of radiology and pathology. <i>Blood Reviews</i> , 2021 , 45, 100693	11.1	1
34	Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all "non-adverse" risk AML. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1510-1513	1.9	1
33	A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. <i>International Journal of Hematology</i> , 2018 , 108, 267-273	2.3	1
32	Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101849	2.2	1
31	Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice.. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022 ,	5.4	1
30	Routine Use of Gemtuzumab Ozogamicin in 7+3-Based Inductions for All "Non-Adverse" Risk AML. <i>Blood</i> , 2020 , 136, 36-37	2.2	0
29	Sustained Complete Molecular Remission With Imatinib Monotherapy in a Child Presenting With Blast Phase -Associated Myeloid Neoplasm With Eosinophilia. <i>HemaSphere</i> , 2020 , 4, e486	0.3	0
28	Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis: Hematologic and Bone Marrow Responses from the Phase 2 Open-Label, Single-Arm, Pathfinder Study. <i>Blood</i> , 2021 , 138, 2565-2565	2.2	0
27	Bioluminescent Imaging of Human Leukemic Stem Cell Engraftment.. <i>Blood</i> , 2005 , 106, 696-696	2.2	0

26	Aberrant Regulation of Wnt/Beta-Catenin Pathway Mediators in Chronic Myelogenous Leukemia Stem Cells.. <i>Blood</i> , 2006 , 108, 2135-2135	2.2	○
25	Myeloid/Lymphoid Neoplasms with Eosinophilia and TKI Fusion Genes: Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, S66-S68	2	○
24	Myelophthistic marrow involved by breast cancer and acute myeloid leukemia. <i>Blood</i> , 2018 , 131, 1036	2.2	
23	Eosinophilia, Eosinophil-Associated Diseases, Eosinophilic Leukemias, and the Hypereosinophilic Syndromes 2018 , 1151-1169		
22	Eosinophilic Myeloproliferative Disorders 2014 , 167-175		
21	Chronic Eosinophilic Leukemia/ Hypereosinophilic Syndrome 2008 , 69-106		
20	Hypereosinophilic Syndrome 2007 , 235-251		
19	Platelet Transcriptome Yields Progressive Markers in Chronic Myeloproliferative Neoplasms and Identifies Putative Targets of Therapy. <i>Blood</i> , 2021 , 138, 1469-1469	2.2	
18	Increased Expression of CD47 Is a Constant Marker in Mouse and Human Myeloid Leukemias.. <i>Blood</i> , 2005 , 106, 3260-3260	2.2	
17	Gene Expression Profile of Idiopathic Thrombocytopenic Purpura (ITP) Reveals Elevated Expression of Interferon Regulated Genes.. <i>Blood</i> , 2006 , 108, 702-702	2.2	
16	Dameshek Smiles: Molecular Clues to the Chronic Myeloproliferative Disorders Unmasked 2007 , 385-398		
15	Large Granular Lymphocyte Leukemia: Clonality Reconsidered.. <i>Blood</i> , 2007 , 110, 3102-3102	2.2	
14	Clinical Utility of a Multi-Gene Next-Generation Sequencing Myeloid Panel in an Academic Hematology Practice. <i>Blood</i> , 2019 , 134, 1408-1408	2.2	
13	Tyrosine Kinase Inhibitors in Systemic Mastocytosis 2020 , 257-265		
12	A Phase 2 Study to Evaluate the Efficacy and Safety of Simtuzumab in Adult Subjects with Primary, Post Polycythemia Vera (PV) or Post Essential Thrombocythemia (ET) Myelofibrosis. <i>Blood</i> , 2015 , 126, 2810-2810	2.2	
11	Eosinophilic Disorders: Differential Diagnosis and Management 2011 , 181-203		
10	A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2010 , 116, 3288-3288	2.2	
9	Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation StatusBased Treatment Stratification. <i>Blood</i> , 2010 , 116, 3313-3313	2.2	

8	A Truncation Mutant of CSF3R, Identified As a Novel Driver in De Novo Myeloid Leukemia, Signals Through TNK2, and Is Responsive to Dasatinib.. <i>Blood</i> , 2012 , 120, 2412-2412	2.2
7	Whole Genome Sequence Analysis of Primary Myelofibrosis.. <i>Blood</i> , 2012 , 120, 2863-2863	2.2
6	Azacitidine Plus Lenalidomide for Untreated AML Patients Ineligible for Conventional Chemotherapy. <i>Blood</i> , 2012 , 120, 3575-3575	2.2
5	Correlation of Symptom Assessment with Genotyping Analysis of Saliva Samples in a Large Cohort of Myeloproliferative Neoplasm Patients. <i>Blood</i> , 2012 , 120, 1732-1732	2.2
4	Change In Albumin Levels During Induction Predicts Survival Outcomes In Adult Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013 , 122, 1403-1403	2.2
3	The CSF3R T618I Mutation Found In Chronic Neutrophilic Leukemia Removes An O-Linked Glycosylation Site and Increases Receptor Dimerization. <i>Blood</i> , 2013 , 122, 270-270	2.2
2	The Beta-Subunit Of Heterotrimeric G Proteins Harbors Gain-Of-Function Mutations In Multiple Hematologic Malignancies. <i>Blood</i> , 2013 , 122, 2510-2510	2.2
1	Chronic Eosinophilic Leukemia: Diagnosis and Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, S27-S29	2